



Company Overview

CohBar (NASDAQ:CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of age-related diseases. MBTs originate from the discovery by CohBar's founders of a novel group of peptides within the mitochondrial genome which regulate metabolism and cell death, and whose biological activity declines with age. CohBar's efforts focus on the development of these mitochondrial-derived peptides (MDPs) into clinically relevant MBTs that offer the potential to address a broad range of age-related diseases, including obesity, nonalcoholic steatohepatitis (NASH), Type 2 diabetes, cancer, and cardiovascular and neurodegenerative diseases. To date, the Company and its founders have discovered more than 100 MDPs.

CohBar Appoints Philippe P. Calais, Pharm.D., Ph.D. as Interim Chief Executive Officer

Dec 10 2018, 4:05 PM EST

CohBar Founder Dr. Nir Barzilai Awarded the 2018 Fondation IPSEN Longevity Prize

Nov 26 2018, 9:00 AM EST

CohBar Reports Third Quarter 2018 Financial Results and Provides Business Update

Nov 14 2018, 4:03 PM EST

Stock Overview

Symbol CWBR
Exchange Nasdaq
Market Cap 166.82m
Last Price \$3.92
52-Week \$2.55 - \$10.789

12/14/2018 04:00 PM EST

Investor Relations

Jon Stern, COO
Investor Relations
T: (650) 446-7888
jon.stern@cohbar.com

Management Team

Philippe P. Calais, Pharm. D., Ph.D.

Chief Executive Officer

Kenneth C. Cundy, Ph.D.

Chief Scientific Officer

Jeffrey F. Biunno, CPA, MBA

Chief Financial Officer, Secretary and Treasurer

Jon L. Stern, MBA

Chief Operating Officer, Director

CohBar, Inc.

1455 Adams Drive
Suite 2050
Menlo Park, CA 94025

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.